MP
AXSM icon

Mangrove Partners’s Axsome Therapeutics AXSM Stock Holding History

Mangrove Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-328,400
Closed -$13.6M – 520
2022
Q1 		$13.6M Sell
328,400
-71,600
-18% -$2.22M 0.73% 17
2021
Q4 		$15.1M Buy
+400,000
New +$14.7M 0.9% 11

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Mangrove Partners's AXSM Position: Q3 2022 in Review

Mangrove Partners sold out of Axsome Therapeutics (AXSM) in Q3 2022, closing a stake of 199,431 shares — an estimated $7.64M sold.

Mangrove Partners first reported a position in AXSM in Q1 2022 and held it in 2 quarters. The position peaked at $7.64M in Q2 2022. 187 funds tracked by Wall St. Rank hold AXSM as of Q3 2022.

  • Mangrove Partners reported no remaining Axsome Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Mangrove Partners sold 199,431 Axsome Therapeutics shares in Q3 2022, an estimated $7.64M.
  • Mangrove Partners first reported a position in Axsome Therapeutics in Q1 2022 and held it in 2 quarters.
  • Mangrove Partners's Axsome Therapeutics position peaked at $7.64M in Q2 2022.
  • 187 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2022.

Based on Mangrove Partners's 13F filing for Q3 2022, filed 14 Nov 2022.